BioSpace News Archive

Atom Bioscience announced completion of a D-round financing of approximately $83 million for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout.

Enterome announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology Congress 2023, to take place on October 20-23, 2023 in Madrid, Spain.

Rockwell Medical, Inc. announced that it will release its financial and operational results for the third quarter ended September 30, 2023 on Tuesday, November 14, 2023.

Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.

Abbisko Therapeutics Co., Ltd. announced that the results of the company’s two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference be held in Boston, U.S. These two research results respectively demonstrate the latest preclinical research progress of the next generation of PRMT5*MTA inhibitors and small molecule brain penetrant PD-L1 inhibitors in Abbisko’s pipeline.

BD announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253.

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial were presented at The Retina Society 56th Annual Scientific Meeting.

BerGenBio ASA announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists Annual Meeting 2023, to be held October 20-24 in Madrid.

LegoChem Biosciences Inc. and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies, building on a previously announced 2022 collaboration and license agreement.